- Home
- PLX vs IMMR Comparison
PLX vs IMMR Comparison
Compare PLX & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- IMMR
- Stock Information
- Founded
- PLX 1993
- IMMR 1993
- Country
- PLX United States
- IMMR United States
- Employees
- PLX N/A
- IMMR N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- IMMR Computer peripheral equipment
- Sector
- PLX Health Care
- IMMR Technology
- Exchange
- PLX Nasdaq
- IMMR Nasdaq
- Market Cap
- PLX 204.9M
- IMMR 232.6M
- IPO Year
- PLX 1998
- IMMR 1999
- Fundamental
- Price
- PLX $1.85
- IMMR $6.92
- Analyst Decision
- PLX Strong Buy
- IMMR Strong Buy
- Analyst Count
- PLX 1
- IMMR 2
- Target Price
- PLX $15.00
- IMMR $12.25
- AVG Volume (30 Days)
- PLX 1.1M
- IMMR 438.1K
- Earning Date
- PLX 11-13-2025
- IMMR 09-11-2025
- Dividend Yield
- PLX N/A
- IMMR 2.60%
- EPS Growth
- PLX N/A
- IMMR 57.07
- EPS
- PLX 0.08
- IMMR 2.04
- Revenue
- PLX $61,948,000.00
- IMMR $163,133,000.00
- Revenue This Year
- PLX $14.53
- IMMR $988.71
- Revenue Next Year
- PLX $75.77
- IMMR $109.72
- P/E Ratio
- PLX $24.02
- IMMR $3.46
- Revenue Growth
- PLX 62.79
- IMMR 338.21
- 52 Week Low
- PLX $1.01
- IMMR $6.47
- 52 Week High
- PLX $3.10
- IMMR $10.72
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- IMMR 44.47
- Support Level
- PLX $2.31
- IMMR $6.96
- Resistance Level
- PLX $2.55
- IMMR $7.24
- Average True Range (ATR)
- PLX 0.15
- IMMR 0.24
- MACD
- PLX -0.06
- IMMR -0.02
- Stochastic Oscillator
- PLX 23.70
- IMMR 30.67
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.